INmune Bio is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co. has two product platforms: dominant negative tumor necrosis factor, which is being developed for Alzheimer's and treatment resistant depression (XPro) and cancer (INB03); and Natural Killer Cell Priming Platform, which utilizes a precision medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation. The INMB stock yearly return is shown above.
The yearly return on the INMB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INMB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|